| David J. Cerveny |
| Chief Legal Officer |
| (339) 970-7011 |
| d.cerveny@uniQure.com |
November 22, 2019
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Lisa Vanjoske and Angela Connell
Re: uniQure N.V.
Form 10-K for the Fiscal Year Ended December 31, 2018
Filed February 28, 2019
File No. 001-36294
Ladies and Gentlemen:
This letter is submitted by uniQure N.V. (the “Company”) in response to your letter to Matthew Kapusta, Chief Executive Officer of the Company, dated November 6, 2019, relating to the above-referenced filing (the “Form 10-K”) by the Company. The Company acknowledges it has received your letter and that it will conform its disclosure in future filings to comply with the comments therein.
If you have any questions regarding this response letter or the Form 10-K, please contact either me (using the contact information provided above) or our counsel, Morgan, Lewis & Bockius LLP, by calling Timothy J. Corbett at +44.20.3201.5690.
Very truly yours, |
| |
|
| |
UNIQURE N.V. |
| |
|
| |
By: | /s/ David J. Cerveny |
|
David J. Cerveny |
| |
Chief Legal Officer |
| |
CC: Matthew Kapusta, Chief Executive Officer & Chief Financial Officer
Timothy J. Corbett, Esq., Morgan, Lewis & Bockius LLP